I. Mellman, G. Coukos, and G. Dranoff, Cancer immunotherapy comes of age, Nature, vol.9, issue.7378, pp.480-489, 2011.
DOI : 10.1038/nri2506

S. A. Rosenberg, IL-2: The First Effective Immunotherapy for Human Cancer, The Journal of Immunology, vol.192, issue.12, pp.5451-5458, 2014.
DOI : 10.4049/jimmunol.1490019

G. C. Cesana, G. Deraffele, S. Cohen, D. Moroziewicz, J. Mitcham et al., Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or Renal Cell Carcinoma, Journal of Clinical Oncology, vol.24, issue.7, pp.1169-1177, 2006.
DOI : 10.1200/JCO.2005.03.6830

T. A. Waldmann, The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design, Nature Reviews Immunology, vol.153, issue.8, pp.595-601, 2006.
DOI : 10.1146/annurev.immunol.14.1.397

F. Mattei, G. Schiavoni, F. Belardelli, and D. F. Tough, IL-15 Is Expressed by Dendritic Cells in Response to Type I IFN, Double-Stranded RNA, or Lipopolysaccharide and Promotes Dendritic Cell Activation, The Journal of Immunology, vol.167, issue.3, pp.1179-1187, 2001.
DOI : 10.4049/jimmunol.167.3.1179

M. P. Rubinstein, A. N. Kadima, M. L. Salem, C. L. Nguyen, W. E. Gillanders et al., Systemic Administration of IL-15 Augments the Antigen-Specific Primary CD8+ T Cell Response Following Vaccination with Peptide-Pulsed Dendritic Cells, The Journal of Immunology, vol.169, issue.9, pp.4928-4935, 2002.
DOI : 10.4049/jimmunol.169.9.4928

S. Dubois, J. Mariner, T. A. Waldmann, and Y. Tagaya, IL-15R?? Recycles and Presents IL-15 In trans to Neighboring Cells, Immunity, vol.17, issue.5, pp.537-547, 2002.
DOI : 10.1016/S1074-7613(02)00429-6
URL : https://doi.org/10.1016/s1074-7613(02)00429-6

E. Mortier, A. Quéméner, P. Vusio, I. Lorenzen, Y. Boublik et al., Soluble Interleukin-15 Receptor ?? (IL-15R??)-sushi as a Selective and Potent Agonist of IL-15 Action through IL-15R??/??, Journal of Biological Chemistry, vol.318, issue.3, pp.1612-1619, 2006.
DOI : 10.1038/nbt0297-142
URL : http://www.jbc.org/content/281/3/1612.full.pdf

G. Bouchaud, L. Garrigue-antar, V. Solé, A. Quéméner, Y. Boublik et al., 230 The exon 3-encoded domain of IL-15Ralpha contributes to IL-15 high-affinity binding and is crucial for IL-15 antagonistic effect of soluble IL-15Ralpha, Cytokine, vol.43, issue.3, pp.1-12, 2008.
DOI : 10.1016/j.cyto.2008.07.294

A. Bessard, V. Solé, G. Bouchaud, A. Quéméner, and Y. Jacques, High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor ?? fusion protein, in metastatic melanoma and colorectal cancer, Molecular Cancer Therapeutics, vol.8, issue.9, pp.2736-2745, 2009.
DOI : 10.1158/1535-7163.MCT-09-0275
URL : http://mct.aacrjournals.org/content/molcanther/8/9/2736.full.pdf

M. Vincent, A. Bessard, D. Cochonneau, G. Teppaz, V. Sole et al., Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency, International Journal of Cancer, vol.11, issue.3, pp.757-765, 2013.
DOI : 10.1158/1535-7163.MCT-12-0019
URL : http://onlinelibrary.wiley.com/doi/10.1002/ijc.28059/pdf

M. Vincent, G. Teppaz, L. Lajoie, V. Solé, A. Bessard et al., Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse, mAbs, vol.70, issue.4, pp.1026-1037, 2014.
DOI : 10.1016/j.canlet.2009.12.004
URL : https://hal.archives-ouvertes.fr/hal-01680794

C. Badoual, S. Hans, N. Merillon, C. Van-ryswick, P. Ravel et al., PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer, Cancer Research, vol.73, issue.1, pp.128-138, 2013.
DOI : 10.1158/0008-5472.CAN-12-2606
URL : http://cancerres.aacrjournals.org/content/canres/73/1/128.full.pdf

A. R. Sánchez-paulete, F. J. Cueto, M. Martínez-lópez, S. Labiano, A. Morales-kastresana et al., Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells, Cancer Discovery, vol.6, issue.1, pp.71-79, 2016.
DOI : 10.1158/2159-8290.CD-15-0510

M. M. Gubin, X. Zhang, H. Schuster, E. Caron, J. P. Ward et al., Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens, Nature, vol.102, issue.7528, pp.577-581, 2014.
DOI : 10.1073/pnas.0506580102
URL : http://europepmc.org/articles/pmc4279952?pdf=render

H. Matsushita, M. D. Vesely, D. C. Koboldt, C. G. Rickert, R. Uppaluri et al., Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting, Nature, vol.1, issue.7385, pp.400-404, 2012.
DOI : 10.1016/1074-7613(94)90087-6
URL : http://europepmc.org/articles/pmc3874809?pdf=render

D. Hannani, M. Vétizou, D. Enot, S. Rusakiewicz, N. Chaput et al., Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25, Cell Research, vol.63, issue.2, pp.208-224, 2015.
DOI : 10.4161/cbt.21782

K. Sakuishi, L. Apetoh, J. M. Sullivan, B. R. Blazar, V. K. Kuchroo et al., Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity, The Journal of Experimental Medicine, vol.208, issue.6, pp.1331-2187, 2010.
DOI : 10.1084/jem.201006432011512c
URL : http://jem.rupress.org/content/jem/208/6/1331.full.pdf

M. A. Cheever, Twelve immunotherapy drugs that could cure cancers, Immunological Reviews, vol.174, issue.1, pp.357-368, 2008.
DOI : 10.4049/jimmunol.174.5.2476

J. Wu, IL-15 agonists: the cancer cure cytokine, J. Mol. Genet. Med, vol.7, p.85, 2013.

H. Perdreau, E. Mortier, G. Bouchaud, V. Solé, Y. Boublik et al., Different dynamics of IL-15R activation following IL-15 cis-or transpresentation, Eur. Cytokine Netw, vol.21, pp.297-307, 2010.
DOI : 10.1016/j.cyto.2010.07.129

R. J. Johnston, L. Comps-agrar, J. Hackney, X. Yu, M. Huseni et al., The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function, Cancer Cell, vol.26, issue.6, pp.923-937, 2014.
DOI : 10.1016/j.ccell.2014.10.018
URL : https://doi.org/10.1016/j.ccell.2014.10.018

J. Duraiswamy, K. M. Kaluza, G. J. Freeman, and G. Coukos, Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors, Cancer Research, vol.73, issue.12, pp.3591-3603, 2013.
DOI : 10.1158/0008-5472.CAN-12-4100
URL : http://cancerres.aacrjournals.org/content/canres/73/12/3591.full.pdf

K. Kim, A. D. Skora, Z. Li, Q. Liu, A. J. Tam et al., Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells, Proc. Natl. Acad. Sci. USA, pp.11774-11779, 2014.

A. Snyder, J. D. Wolchok, and T. A. Chan, Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma, New England Journal of Medicine, vol.371, issue.23, p.783, 2015.
DOI : 10.1056/NEJMoa1406498

E. M. Van-allen, D. Miao, B. Schilling, S. A. Shukla, C. Blank et al., Genomic correlates of response to CTLA-4 blockade in metastatic melanoma, Science, vol.28, issue.11, pp.207-211, 2015.
DOI : 10.1093/bioinformatics/bts196

N. A. Rizvi, M. D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov et al., Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, vol.105, issue.51, pp.124-128, 2015.
DOI : 10.1073/pnas.0810114105
URL : http://europepmc.org/articles/pmc4993154?pdf=render

D. T. Le, J. N. Uram, H. Wang, B. R. Bartlett, H. Kemberling et al., PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, New England Journal of Medicine, vol.372, issue.26, pp.2509-2520, 2015.
DOI : 10.1056/NEJMoa1500596
URL : http://europepmc.org/articles/pmc4481136?pdf=render

P. Yu, J. C. Steel, M. Zhang, J. C. Morris, R. Waitz et al., Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model, Proc. Natl. Acad. Sci. USA, pp.6187-6192, 2012.
DOI : 10.4049/jimmunol.1000661
URL : http://www.pnas.org/content/109/16/6187.full.pdf

A. L. Kinter, E. J. Godbout, J. P. Mcnally, I. Sereti, G. A. Roby et al., The Common ??-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands, The Journal of Immunology, vol.181, issue.10, pp.6738-6746, 2008.
DOI : 10.4049/jimmunol.181.10.6738

C. S. Hsieh, S. E. Macatonia, A. O. Garra, and K. M. Murphy, T cell genetic background determines default T helper phenotype development in vitro, Journal of Experimental Medicine, vol.181, issue.2, pp.713-721, 1995.
DOI : 10.1084/jem.181.2.713
URL : http://jem.rupress.org/content/jem/181/2/713.full.pdf

D. B. Corry, S. L. Reiner, P. S. Linsley, and R. M. Locksley, Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis, J. Immunol, vol.153, pp.4142-4148, 1994.

C. E. Johnston, J. E. Bradley, J. M. Behnke, K. R. Matthews, and K. J. Else, Isolates of Trichuris muris elicit different adaptive immune responses in their murine host, Parasite Immunology, vol.71, issue.2, pp.69-78, 2005.
DOI : 10.1128/IAI.71.7.4171-4174.2003

C. Aspord, M. T. Leccia, J. Charles, and J. Plumas, Plasmacytoid Dendritic Cells Support Melanoma Progression by Promoting Th2 and Regulatory Immunity through OX40L and ICOSL, Cancer Immunology Research, vol.1, issue.6, pp.402-415, 2013.
DOI : 10.1158/2326-6066.CIR-13-0114-T
URL : http://cancerimmunolres.aacrjournals.org/content/canimm/1/6/402.full.pdf

M. Tosolini, A. Kirilovsky, B. Mlecnik, T. Fredriksen, S. Mauger et al., Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer, Cancer Research, vol.71, issue.4, pp.1263-1271, 2011.
DOI : 10.1158/0008-5472.CAN-10-2907

W. K. Nevala, C. M. Vachon, A. A. Leontovich, C. G. Scott, M. A. Thompson et al., Evidence of Systemic Th2-Driven Chronic Inflammation in Patients with Metastatic Melanoma, Clinical Cancer Research, vol.15, issue.6, pp.1931-1939
DOI : 10.1158/1078-0432.CCR-08-1980
URL : http://clincancerres.aacrjournals.org/content/clincanres/15/6/1931.full.pdf

T. Kusuda, K. Shigemasa, K. Arihiro, T. Fujii, N. Nagai et al., Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer, Oncology Reports, vol.13, pp.1153-1158, 2005.
DOI : 10.3892/or.13.6.1153

C. Robert, G. V. Long, B. Brady, C. Dutriaux, M. Maio et al., Mutation, New England Journal of Medicine, vol.372, issue.4, pp.320-330, 2015.
DOI : 10.1056/NEJMoa1412082
URL : https://hal.archives-ouvertes.fr/hal-00699117

C. Robert, J. Schachter, G. V. Long, A. Arance, J. J. Grob et al., Pembrolizumab versus Ipilimumab in Advanced Melanoma, KEYNOTE-006 Investigators. 2015. Pembrolizumab versus Ipilimumab in Advanced Melanoma, pp.2521-2532
DOI : 10.1056/NEJMoa1503093

M. Zhang, Z. Yao, S. Dubois, W. Ju, J. R. M? et al., Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer, Proc. Natl. Acad. Sci. USA, pp.7513-7518, 2009.
DOI : 10.4049/jimmunol.176.1.309
URL : http://www.pnas.org/content/106/18/7513.full.pdf